» Articles » PMID: 18774558

What is the Preferred GnRH Analogue for Polycystic Ovary Syndrome Patients Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization?

Overview
Journal Fertil Steril
Date 2008 Sep 9
PMID 18774558
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

In an attempt to evaluate the influence of the GnRH analogue used during controlled ovarian hyperstimulation (COH) on the outcome of IVF cycles of polycystic ovary syndrome (PCOS) patients, we studied 152 IVF cycles. The PCOS patients undergoing COH using the GnRH agonist protocol (n = 50) showed a significantly higher pregnancy rate (36% vs. 19.6%, respectively), compared with the GnRH antagonist protocol (n = 102).

Citing Articles

Live Birth Outcomes for PCOS Patients Under the Follicular-Phase Long-Acting GnRH Agonist Protocol or Antagonist Protocol - A Retrospective Chinese Cohort.

Zhai J, Zhang J, He J, Lv M, Zhang B, Li G J Multidiscip Healthc. 2023; 16:2781-2792.

PMID: 37753342 PMC: 10518358. DOI: 10.2147/JMDH.S432936.


Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.

Kadoura S, Alhalabi M, Nattouf A Sci Rep. 2022; 12(1):4456.

PMID: 35292717 PMC: 8924277. DOI: 10.1038/s41598-022-08400-z.


Comparative Effectiveness of Three Ovarian Hyperstimulation Protocol in In Vitro Fertilization (IVF) Cycles for Women with Polycystic Ovary Syndrome.

Chen Y, Zhao J, Zhang H Med Sci Monit. 2018; 24:9424-9428.

PMID: 30591703 PMC: 6322365. DOI: 10.12659/MSM.913757.


Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome.

Lai Q, Xiang W, Li Q, Zhang H, Li Y, Zhu G Front Med. 2017; 12(5):518-524.

PMID: 29260383 DOI: 10.1007/s11684-017-0575-y.


Treatment Outcome of Ovulation-inducing Agents in Patients with Anovulatory Infertility: A Prospective, Observational Study.

Prajapati K, Desai M, Shah S, Choudhary S, Aggarwal R, Mishra V J Pharmacol Pharmacother. 2017; 8(3):116-121.

PMID: 29081619 PMC: 5642124. DOI: 10.4103/jpp.JPP_43_17.